Physician profile
Lisa G Easterling
NPI 1649609397
$5,396.44
in general payments reported to CMS, 2019-2025
21 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $722 · 2023: $2,015 · 2024: $940 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Travel and Lodging: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.09 |
| Travel and Lodging | $754.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,118.48 | 2023 | Micra, Linq II |
| Novartis Pharmaceuticals Corporation | $612.18 | 2022-2025 | |
| Irhythm Technologies, INC. | $561.68 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $409.93 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $347.92 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.31 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.72 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $233.94 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $216.86 | 2024-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $201.51 | 2024-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $195.87 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $195.25 | 2024-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $165.52 | 2021-2022 | |
| Abbott Laboratories | $131.70 | 2022-2023 | Quadra Assura, Allure Quadra |
| Boston Scientific Corporation | $97.25 | 2024-2025 | Watchman Flx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $96.75 | 2024-2025 | Synergy Ablation System |
| Bard Peripheral Vascular, INC. | $74.06 | 2021 | |
| Lilly USA, LLC | $54.69 | 2023-2025 | Mounjaro, Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.34 | 2025 | Lifevest |
| Inspire Medical Systems, INC. | $21.50 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $15.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.